Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $14.307 million which missed the analyst consensus estimate of $14.400 million by 0.65 percent. This is a 39.53 percent increase over sales of $10.254 million the same period last year.